spacer
home > ebr > summer 2002 > post-translational modifications of biopharmaceuticals - a challenge for analytical characterisation
PUBLICATIONS
European Biopharmaceutical Review

Post-Translational Modifications of Biopharmaceuticals - A Challenge for Analytical Characterisation

The list of biopharmaceuticals produced by recombinant DNA technology, transgenics and synthetic manufacture continues to grow to encompass therapeutic and diagnostic agents ranging from antibodies to vaccines. Regardless of the method of production, all these products present the biotechnology community with complex challenges in manufacture and, ultimately, analytical characterisation. Recognising the importance of this topic, a recent international conference was held on 'The Impact of Post-Translational and Chemical Modifications on Protein Therapeutics' (1). At this meeting of leading scientists from academia and industry, a keynote address was given by Dr Keith Weber, Deputy Director, Division of Monoclonal Antibodies, Office of Therapeutics Research and Review, Center for Biologics Evaluation and Research (CBER), FDA. Dr Weber presented the current CBER perspective on post-translational and chemical modifications, emphasising above all that CBER's primary concerns are "safety, purity, potency and strength of bioproducts".


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Fiona Greer and Dr Andrew Reason of M-Scan Ltd (UK) and Dr Mark Rogers of M-Scan Inc (US)
Dr Fiona Greer, Dr Andrew Reason and Dr Mark Rogers are principals of M-Scan (Mass Spectrometry Consultants and Analysts). Together, they have over 45 years' experience in the analysis of proteins and carbohydrates using mass spectrometry.
Following a PhD in Protein Biochemistry from Aberdeen University, Fiona joined M-Scan in 1984 to develop analytical services using the then new techniques of biopolymer mass spectrometry. She is Director of Biochemistry and VP of M-Scan Ltd, M-Scan SA and M-Scan Inc, and is also responsible for QA at all three laboratories.
Andrew received his PhD in Biochemistry from Imperial College, University of London in 1992 and joined M-Scan in 1994. He is Managing Director of M-Scan Ltd, Wokingham, UK.
Mark received his PhD in Biochemistry from the University of Westminster, London and has been with M-Scan for 13 years. He is currently Vice President of M-Scan Inc, Pennsylvania, US.

spacer
Dr Fiona Greer
spacer
spacer
spacer
Dr Andrew Reason
spacer
spacer
spacer
Dr Mark Rogers
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system
More info >>

White Papers
 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement